Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) plans to invest in a new R&D facility and expand its presence in the San Francisco Bay Area.
The investment will support the leasing and construction of the state-of-the-art R&D facility in the global innovation center of South San Francisco.
The expansion will allow the company to focus on main interdisciplinary capabilities, such as data science and biology to fuel a step-change in how it creates medicine.
Janssen's researchers at the new facility will be put to work on infectious and retinal diseases, data science and emerging modalities within discovery, product development, and supply.
Upon completion of construction, the expanded facility is projected to more than double Janssen's presence in San Francisco and is expected to be fully operational in 2022.
The investment will allow Janssen to continue ‘world class discovery’ and will also increase its capabilities to merge with other companies on various research and discovery projects.
However, the investment amount has been undisclosed.
|Name||Janssen Pharmaceutical Companies of Johnson & Johnson|